Advertisement

Regulatory Considerations and Companion Diagnostics

  • Elizabeth VanAlphen
  • Omar Perez
Chapter
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

The combination of a small molecule and a biologic in an ADC has consequences for regulatory requirements and guidances with respect to nonclinical evaluation as well as clinical development. The complexity of ADCs with regards to manufacturing and analytics presents additional challenges from the regulatory perspective. The clinical development of most ADCs involves patient selection; companion diagnostic products are regulated as a medical device in the US and in most ex-US markets and require a development plan that is integrated with the clinical development strategy from the earliest stages.

Keywords

Regulatory FDA Companion diagnostic Precision medicine Patient selection GLP GMP Manufacturing 

References

  1. 1.
    Rowe JM, Lowenberg B (2013) Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood 121(24):4838–4841CrossRefPubMedGoogle Scholar
  2. 2.
    FDA Approved Drug Products (2017) MYLOTARG 2017 BLA. Accessdata.fda.gov. U.S. Food and Drug Administration, N.p, n.d Web. 15Google Scholar
  3. 3.
    FDA Approved Drug Products (2017) ADCETRIS 2011 BLA. Accessdata.fda.gov. N.p., n.d. Web. 31Google Scholar
  4. 4.
    FDA Approved Drug Products (2017) KADCYLA (ado-trastuzumab emtansine, T-DM1) 2013 BLA. Accessdata.fda.gov. N.p., n.d. Web. 31Google Scholar
  5. 5.
    FDA Approved Drug Products (2017) BESPONSA 2017 BLA. Accessdata.fda.gov. U.S. Food and Drug Administration, N.p, n.d. Web 15 Dec 2017Google Scholar
  6. 6.
    S9 Implementation Working Group ICH S9 Guideline (2016) Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and AnswersGoogle Scholar
  7. 7.
    ICH Harmonised Tripartite Guideline nonclinical evaluation for anticancer pharmaceuticals S9 (2009)Google Scholar
  8. 8.
    ICH Harmonised Tripartite Guideline Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals S6(R1) (2011)Google Scholar
  9. 9.
    Saber H, Leighton JK (2015) An FDA oncology analysis of antibody-drug conjugates. Regul Toxicol Pharmacol 71(3):444–452CrossRefPubMedGoogle Scholar
  10. 10.
    Food and Drug Administration Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research (2014) Guidance for industry: expedited programs for serious conditions – drugs and biologics. FDA, MarylandGoogle Scholar
  11. 11.
    Beaver JA, Tzou A, Blumenthal GM, McKee AE, Kim G, Pazdur R, Philip R (2017) An FDA perspective on the regulatory implications of complex signatures to predict response to targeted therapies. Clin Cancer Res 23(6):1368–1372CrossRefPubMedGoogle Scholar
  12. 12.
    Li M (2014) Statistical consideration and challenges in bridging study of personalized medicine. J Biopharm Stat 25(3):397–407CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Pfizer Inc., Worldwide Safety and RegulatoryGrotonUSA
  2. 2.Pfizer Inc., DiagnosticsSouth San FranciscoUSA

Personalised recommendations